PerSimiO
Predicting Fracture Risk for Patients with Cancer and Osteoporosis
Company Overview
Snapshot
Founded in January 2015 by Prof. Zohar Yosibash, Dr. Nir Trabelsi, and Prof. MD Charles Milgrom, PerSimiO operates with 1–10 employees. The company has secured $955K in total capital across two funding rounds. PerSimiO's technology, a CT-based prediction model to simulate the response of human bones to load, was developed in 2015.
Business overview
PerSimiO is a health tech and life sciences company that develops superior prediction technology for assessing fracture risk in patients with cancer and osteoporosis. Its core technology is based on proprietary simulation of human bone response to load, validated through ex-vivo experiments using routine CT scans. The company offers a fully automated web-service, which can be integrated into hospital PACS or accessed as a locally hosted web-application, targeting the diagnosis and treatment of conditions like osteoporosis, metastatic tumors, and bone-weakening injuries. PerSimiO operates in the digital healthcare and medical decision support sectors, serving healthcare providers globally with products such as Simfini-TUMOR, Simfini-IMPLANT, Simfini-OSTEO, Simfini-DIABETES, and Simfini-SENIOR.
Log in to access full profile ›Company Intelligence Q&A
- What is PerSimiO's primary focus?
- PerSimiO focuses on predicting fracture risk for patients with cancer and osteoporosis using a superior prediction technology based on proprietary simulation of human bone response to load.
- When was PerSimiO founded?
- PerSimiO was founded in January 2015 by Prof. Zohar Yosibash, Dr. Nir Trabelsi, and Prof. MD Charles Milgrom.
- What is the core technology behind PerSimiO's products?
- PerSimiO's patented technology is a fully automated web-service that simulates the response of human bones to load, validated by ex-vivo experiments on human femurs using routine CT scans.
- Which organizations have provided grants to PerSimiO?
- In August 2017, PerSimiO received a grant from the Israel Innovation Authority. In October 2015, the company secured a grant from the Office of the Chief Scientist.
- What are some of the products offered by PerSimiO?
- PerSimiO offers products such as Simfini-TUMOR, Simfini-IMPLANT, Simfini-OSTEO, Simfini-DIABETES, and Simfini-SENIOR, designed to assess bone strength and optimize treatment for various conditions.